Skip to main content

Konstantinov Konstantin's Form 4 filing

Codiak BioSciences, Inc.CDAK · filed Sep 28, 2021

Accession no.
0000899243-21-038063
Filed
Sep 28, 2021
Trade date
Jun 8, 2021
Filing delay
112 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $186.3K. It was filed 112 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Konstantinov KonstantinCIK 0001774649Officer (Chief Technology Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 8, 2021Common StockMOption exerciseAcquired+7,276$3.29+$23,938.047,276Direct
Jun 8, 2021Common StockSSaleDisposed−6,272$25.53F3−$160,124.161,004Direct
Jun 8, 2021Common StockSSaleDisposed−1,004$26.04F4−$26,144.160Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 8, 2021Common StockMOption exerciseAcquired+7,276$0.00$092,978Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $25.00 to $25.99 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $26.00 to $26.12 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)